Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead

Thomas Borody, Monika Fischer, Scott Mitchell, Jordana Campbell

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

At its height, the Clostridium difficile infection epidemic caused approximately 7000 infections and 300 deaths per day in the USA. Fecal microbiota transplantation (FMT) has demonstrated extraordinary clinical resolution, C. difficile infection cure rates of over 90%, and low recurrence. In tandem with the rise of FMT, the gastrointestinal microbiome has emerged as a vital organ armed with a wealth of microbe soldiers more powerful than known antibiotics. FMTs reputation has diffused into many new indications yet these appear to be merely the tip of the iceberg when considering its potential applications. FMT as a therapeutic tool has evolved from the original format of blended donor stool and moved towards a refined product comprising a myriad of microbial components, presented aesthetically as encapsulated lyophilized powder.

Original languageEnglish (US)
Pages (from-to)1379-1391
Number of pages13
JournalExpert Review of Gastroenterology and Hepatology
Volume9
Issue number11
DOIs
StatePublished - Nov 2 2015

Keywords

  • antibiotic resistance
  • fecal microbiota transplantation
  • FMT
  • FSM
  • full spectrum microbiota
  • microbiome
  • probiotics

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead'. Together they form a unique fingerprint.

  • Cite this